FDA Accepts Amgen’s Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab
THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s Biologics License Application (BLA) for evolocumab for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a […]